To The Moon

UnitedHealth Group ( $UnitedHealth(UNH)$ ) just stole the spotlight with a 4.5% surge, powering the Dow’s rally as the broader market’s upward climb starts to lose steam. The S&P 500 and Nasdaq are showing cracks, with most of the Magnificent 7 pulling back. Meanwhile, investors are piling into defensive sectors like healthcare. UNH, still nursing a 35% year-to-date loss, is leading this charge. Is this the moment to rethink your portfolio? Let’s dive into the shift, UNH’s potential, and the defensive plays worth your attention. The Market’s New Direction: Safety First The growth-fueled rally that carried markets to new highs is hitting a wall. Economic headwinds—rising oil prices near $75 per barrel amid geopolitical flare-ups, plus looming tr

$UnitedHealth(UNH)$ In a year marked by tech exuberance, speculative growth rebounds, and lingering fears of a macroeconomic slowdown, one of the market’s most consistent performers isn’t a high-flying AI startup or a mega-cap cloud darling—it’s UnitedHealth Group (NYSE: UNH). As one of the largest and most influential players in the healthcare space, UnitedHealth has quietly become a pillar of market stability and predictable growth. While investors chase returns in volatile sectors, UNH is demonstrating that defensive doesn’t mean stagnant. In fact, the company’s strong earnings, durable cash flows, and expanding footprint in both insurance and health services may signal that “defense is the new offense” for long-term portfolios. Its steady rise

1. $Apple(AAPL)$ AAPL looks like the bottom is in 🍎Monthly market bias has been acting as a strong support for the past couple of months.Daily and Weekly BX expanding out of the wedge.Should see all time highs in the next 8 - 12 weeks 🔥Image2. $Advanced Micro Devices(AMD)$ Hoping I would be wrong about the short term top for AMD 🤞That said, happy to took some profits Image3. $UnitedHealth(UNH)$ For the first time since April UNH has a shot at the weekly BX closing green 🟢Smart money zone has tested and held. ✅Once we get confirmation on Friday, I may add this to my watchlist 🏆ImageFor whom haven't open CBA can know more from below:🏦 Open a CBA today and enjoy privi

$UnitedHealth(UNH)$ daily

Performances of all my stocks YTD at the end of H1 2025 :NATAN'S PORTFOLIO: +31.8%S&P500: +5.5% $Robinhood(HOOD)$ +151% $TransMedics Group, Inc.(TMDX)$ +115% $B2Gold(BTG)$ +48% $Alibaba(BABA)$ +34% $Meta Platforms, Inc.(META)$ +26% $Advanced Micro Devices(AMD)$ +17% (sold at +56%) $PDD Holdings Inc(PDD)$ +8% $Edwards Lifesciences(EW)$ +6% $PayPal(PYPL)$ -13% $Regeneron

$聯合健康(UNH)$  

UnitedHealth Sees Growing Chorus of Analysts Cutting Price Target $UnitedHealth(UNH)$   is seeing a growing chorus of analysts cutting their price target on the stock as the US Senate debates Trump's tax bill that includes provisions for potential cuts in Medicaid.  The average price target on the largest US health insurer fell to $365.13 on Tuesday from $373.42 a day earlier, data compiled by Bloomberg show. That price target has tumbled from $609.23 on April 18, a day after the company reported quarterly earnings that missed analysts' estimates for the first time since at least 2014.  Piper Sandler's Jessica Tassan was among the analysts who recently cut their price target on the stock. Tassan lo

Terus meluncurrrrrrrrrrrrrrrrrrr

$UnitedHealth(UNH)$  yes. everyone needs healthcare and this is the biggest player in the US

$UnitedHealth(UNH)$  interesting slide of events! 

$UnitedHealth(UNH)$  Not into pharmaceutical stocks and health care stocks though peeps like Adam Khoo advocates for it and is rather into it. Do your own due diligence and buy what you can stomach. Not my cup of tea. @BABY SPACEROCK  @JiaDeName   Leave a comment for coins.

hello everyone im new in tiger 

$UnitedHealth(UNH)$  Unprofitable business wouldn't buy any shares until it gets under $220

$UnitedHealth(UNH)$   should buy below $285. 

$UnitedHealth(UNH)$  buy when max fear . Now is not max yet . 

$UnitedHealth(UNH)$   UnitedHealth Group (NYSE: UNH) has experienced significant stock volatility in 2025, driven by multiple challenges. The company faces intensified regulatory scrutiny, with the Centers for Medicare and Medicaid Services expanding audits on Medicare Advantage plans, leading to a 7.5% stock decline over two days. Additionally, a Department of Justice investigation into alleged Medicare fraud and a massive cyberattack on its subsidiary, Change Healthcare, have compounded investor concerns. The unexpected death of UnitedHealthcare CEO Brian Thompson further unsettled the company. Despite these setbacks, some analysts view the depressed stock price as a potential buying opportunity, citing historical patterns of recovery i

$UnitedHealth(UNH)$ Alright, I know many investors have been paying close attention to UnitedHealth Group (UNH) lately. The company has been making headlines for a variety of reasons—some positive, some concerning—and its stock price has seen notable movement in recent weeks. Anytime that happens, it naturally generates a wave of interest from both retail and institutional investors trying to figure out: Is this a buy, a hold, or a sell? In this breakdown, I want to dig deeper into the current state of UnitedHealth: what’s driving the volatility, what the company is doing in response, and how investors should interpret the long-term outlook based on current developments. What’s Behind the Recent Stock Volatility? So what’s going on with UnitedHealt

$UnitedHealth(UNH)$  of-course.​

$UnitedHealth(UNH)$  wihh fulll senyum

UnitedHealth Group ( $UnitedHealth(UNH)$ ) is taking a beating. After plummeting from a high of $610 late last year to a recent low of $288.57, the stock staged a fleeting three-day rally—only to sink 6% again following HSBC’s downgrade from "Hold" to "Reduce." New CEO Stephen Hemsley, however, isn’t fazed. He scooped up 86,700 shares at $288.57, dropping $25 million to signal his faith in the battered health insurer. With the stock now hovering at $302.25 and down 40.1% year-to-date, investors are at a crossroads: Is $250 a golden ticket, or a trap waiting to spring? What’s Fueling the Freefall? UNH’s descent isn’t random—it’s a cocktail of pain points shaking investor confidence: Earnings Stumble: Q1 2025 brought an earnings miss, with soaring me

UnitedHealth Group ( $UnitedHealth(UNH)$ ) just stole the spotlight with a 4.5% surge, powering the Dow’s rally as the broader market’s upward climb starts to lose steam. The S&P 500 and Nasdaq are showing cracks, with most of the Magnificent 7 pulling back. Meanwhile, investors are piling into defensive sectors like healthcare. UNH, still nursing a 35% year-to-date loss, is leading this charge. Is this the moment to rethink your portfolio? Let’s dive into the shift, UNH’s potential, and the defensive plays worth your attention. The Market’s New Direction: Safety First The growth-fueled rally that carried markets to new highs is hitting a wall. Economic headwinds—rising oil prices near $75 per barrel amid geopolitical flare-ups, plus looming tr

$UnitedHealth(UNH)$ In a year marked by tech exuberance, speculative growth rebounds, and lingering fears of a macroeconomic slowdown, one of the market’s most consistent performers isn’t a high-flying AI startup or a mega-cap cloud darling—it’s UnitedHealth Group (NYSE: UNH). As one of the largest and most influential players in the healthcare space, UnitedHealth has quietly become a pillar of market stability and predictable growth. While investors chase returns in volatile sectors, UNH is demonstrating that defensive doesn’t mean stagnant. In fact, the company’s strong earnings, durable cash flows, and expanding footprint in both insurance and health services may signal that “defense is the new offense” for long-term portfolios. Its steady rise

1. $Apple(AAPL)$ AAPL looks like the bottom is in 🍎Monthly market bias has been acting as a strong support for the past couple of months.Daily and Weekly BX expanding out of the wedge.Should see all time highs in the next 8 - 12 weeks 🔥Image2. $Advanced Micro Devices(AMD)$ Hoping I would be wrong about the short term top for AMD 🤞That said, happy to took some profits Image3. $UnitedHealth(UNH)$ For the first time since April UNH has a shot at the weekly BX closing green 🟢Smart money zone has tested and held. ✅Once we get confirmation on Friday, I may add this to my watchlist 🏆ImageFor whom haven't open CBA can know more from below:🏦 Open a CBA today and enjoy privi

Performances of all my stocks YTD at the end of H1 2025 :NATAN'S PORTFOLIO: +31.8%S&P500: +5.5% $Robinhood(HOOD)$ +151% $TransMedics Group, Inc.(TMDX)$ +115% $B2Gold(BTG)$ +48% $Alibaba(BABA)$ +34% $Meta Platforms, Inc.(META)$ +26% $Advanced Micro Devices(AMD)$ +17% (sold at +56%) $PDD Holdings Inc(PDD)$ +8% $Edwards Lifesciences(EW)$ +6% $PayPal(PYPL)$ -13% $Regeneron

$UnitedHealth(UNH)$ daily

$聯合健康(UNH)$  

$UnitedHealth(UNH)$ has faced one blow after another this year. First, a top executive was shot. Then, the company missed earnings expectations. The CEO resigned, and the company withdrew its full-year guidance. This week, it was revealed that the company is under criminal investigation for alleged Medicare fraud.These successive shocks have sent the stock price plummeting from $620 to $250 within a month—a 33% drop this month alone and a year-to-date decline of over 55%.In the short term, the stock may be oversold, but it’s hard to rule out further downside if more news about criminal charges emerges.Did the Options Market Know First? How Credible Is the Criminal Allegation?Before The Wall Street Journal published its story, someone secretly short

$UnitedHealth(UNH)$  The Department of Justice (DOJ) is investigating UnitedHealth Group (UNH) for potential Medicare fraud. While specifics remain undisclosed, reports indicate the investigation centers on the company's Medicare Advantage business practices. This is a criminal investigation, separate from a previously reported antitrust investigation concerning the relationship between UNH's insurance division and its Optum health services segment. The antitrust investigation also includes scrutiny of UNH's doctor-group acquisitions and Medicare billing. The ongoing investigations contribute to the uncertainty surrounding UNH's stock performance . The precise timeline of the DOJ's criminal investigation into UnitedHe

After a brutal selloff, UnitedHealth shares staged a three-day rally, climbing to $321.58. The bounce followed CEO Stephen Hemsley's $25 million stock purchase—86,700 shares at $288.57 each—disclosed in a Friday SEC filing.Is this a sign the bottom is in?Would you buy, hold, or sell at $300?Could UNH be on its way back to $400?🎁Special Notes: Whoever showed up on the” What the Tigers Say” column will receive 100 Tiger Coins and an exclusive interview invitation to honor your contribution.Click titles to read the full analysis:1. @yourcelesttyy: Key Points:UNH’s turmoil isn’t just a company story—it’s a bellwether for the healthcare sector:Insider Confidence: Hemsley’s purchase, combined with CFO and other executive buying, signals that

$UnitedHealth(UNH)$ 🚨📰🧠📉 UNH: Weaponised Fear or Wealth Transfer Opportunity? 📉🧠🚨 Sometimes the loudest headlines mask the sharpest setups. Here’s why the $UNH plunge on 22May25, 🇳🇿NZ Time, might be less about scandal, and more about strategy. 📕 The Anatomy of a Narrative-Driven Selloff On 21May25, The Guardian reignited recycled allegations against UnitedHealth Group ($UNH), claiming the insurer quietly incentivised nursing homes to reduce hospital transfers. What they didn’t lead with? The U.S. Department of Justice had already investigated these allegations over multiple years, interviewed witnesses, reviewed thousands of documents, and ultimately declined to pursue prosecution due to “significant factual inaccuracies.” This wasn’t breaking news

UnitedHealth Group ( $UnitedHealth(UNH)$ ) has been a punching bag for the market lately, with its stock cratering after a brutal sell-off. But last Friday, new CEO Stephen Hemsley threw a curveball, scooping up 86,700 shares at $288.57 a pop—totaling a cool $25 million—per an SEC Form 4 filing. At $300, UNH is licking its wounds, but is this insider buy a signal to jump in, or a head-fake before more pain? Let’s break it down and figure out if UNH’s got the legs to sprint back to $400—or if it’s just staggering. The Insider Scoop: Hemsley’s $25M Gambit Hemsley isn’t messing around. Dropping $25 million on UNH shares isn’t pocket change—it’s a neon sign flashing “I believe in this.” Insider buying like this often hints at undervaluation, especially

UnitedHealth Sees Growing Chorus of Analysts Cutting Price Target $UnitedHealth(UNH)$   is seeing a growing chorus of analysts cutting their price target on the stock as the US Senate debates Trump's tax bill that includes provisions for potential cuts in Medicaid.  The average price target on the largest US health insurer fell to $365.13 on Tuesday from $373.42 a day earlier, data compiled by Bloomberg show. That price target has tumbled from $609.23 on April 18, a day after the company reported quarterly earnings that missed analysts' estimates for the first time since at least 2014.  Piper Sandler's Jessica Tassan was among the analysts who recently cut their price target on the stock. Tassan lo

UnitedHealth Group ( $UnitedHealth(UNH)$ ) is taking a beating. After plummeting from a high of $610 late last year to a recent low of $288.57, the stock staged a fleeting three-day rally—only to sink 6% again following HSBC’s downgrade from "Hold" to "Reduce." New CEO Stephen Hemsley, however, isn’t fazed. He scooped up 86,700 shares at $288.57, dropping $25 million to signal his faith in the battered health insurer. With the stock now hovering at $302.25 and down 40.1% year-to-date, investors are at a crossroads: Is $250 a golden ticket, or a trap waiting to spring? What’s Fueling the Freefall? UNH’s descent isn’t random—it’s a cocktail of pain points shaking investor confidence: Earnings Stumble: Q1 2025 brought an earnings miss, with soaring me

After a downgrade and a CEO buy-in, what’s really the prognosis? It’s not every day you see a company shed 40% of its value in a year and still command a $275 billion market cap. But UnitedHealth Group is no ordinary stock. After a bruising slide from its lofty $600+ highs, a modest rally gave investors a flicker of hope—only for HSBC to turn up with a cold stethoscope and a downgrade. The market winced, and $UnitedHealth(UNH)$ promptly dropped 6%. So: was $300 a floor, a trap, or a buying opportunity? Let’s stitch this together. Vital signs meet valuations in healthcare’s high-stakes heartbeat First, the Diagnosis: Is the Valuation Really Sick? Despite the dramatic fall, UNH isn’t exactly trading at junkyard levels. At a trailing P/E of 12.7 and a

UnitedHealth Group ( $UnitedHealth(UNH)$ ) has been on a wild ride, plummeting over 50% year-to-date to a low of $288.57 before staging a three-day rally to $321.66, sparked by new CEO Stephen Hemsley’s bold $25 million purchase of 86,700 shares. This insider move, coupled with other executive buying, has investors buzzing: is this a generational buying opportunity, or a fleeting bounce before more pain? With the stock trading at a discount and questions lingering about a return to $400, let’s unpack the catalysts, risks, and whether you should buy, sell, or hold at $300. 🔍 What’s Happening? UNH’s stock has been battered by a perfect storm of challenges: Earnings Blowup: In Q1 2025, UNH reported a minor earnings miss and withdrew its full-year guid

UnitedHealth Group ( $UnitedHealth(UNH)$ ) has been slammed, dropping 50% year-to-date amid a barrage of brutal headlines. The sudden resignation of CEO Andrew Witty, the scrapping of its full-year earnings outlook, a criminal probe for Medicare fraud, and President Trump’s new drug pricing executive order have investors running for cover. With the stock down another 16% on the fraud probe news alone, the big question looms: Is UNH a screaming buy at these levels, or a disaster to avoid? And what does Trump’s order mean for the biotech sector’s already shaky ground? Let’s break it down. What’s Driving the Chaos? CEO Exit: Andrew Witty stepped down abruptly on Tuesday, leaving UNH without a permanent leader. The move stunned markets, especially afte

UnitedHealth Group ( $UnitedHealth(UNH)$ ) is reeling from a perfect storm of bad news. A criminal probe into alleged Medicare fraud has sent its stock tumbling an additional 16%, compounding an 18% drop triggered by CEO Andrew Witty’s sudden exit and the scrapping of its 2025 earnings outlook. With President Trump’s new drug pricing executive order adding pressure to the healthcare sector, UNH’s stock is down 38% year-to-date, trading near $311. Is this a golden opportunity to buy a beaten-down giant, or a warning to stay away? And will biotech stocks take a bigger hit from Trump’s aggressive pricing push? Let’s dive into the chaos and explore what’s next. 🔍 What’s Happening? Medicare Fraud Probe: The U.S. Department of Justice is investigating UN

Before Buying UNH Dip: Here's What You Should Know UnitedHealth Group faced another setback amid ongoing negative news. On May 21, before the market opened, The Guardian reported that UNH secretly paid bonuses to nursing homes to reduce hospital referrals and help attract more Medicare enrollees. The stock fell as much as 7% in pre-market trading. This month, amid a series of negative events, UnitedHealth's stock price plummeted from its April high of $606 to a low of $248, before rebounding to $321.58 at Tuesday's close. From a long-term perspective, the U.S. health insurance sector had been a veritable "bull market haven": In the 15 years from 2010 to 2025, UNH had surged by 2400% before its recent decline. Other companies in the sector also saw significant gains, with MOH up over 1700%,

$UnitedHealth(UNH)$ Alright, I know many investors have been paying close attention to UnitedHealth Group (UNH) lately. The company has been making headlines for a variety of reasons—some positive, some concerning—and its stock price has seen notable movement in recent weeks. Anytime that happens, it naturally generates a wave of interest from both retail and institutional investors trying to figure out: Is this a buy, a hold, or a sell? In this breakdown, I want to dig deeper into the current state of UnitedHealth: what’s driving the volatility, what the company is doing in response, and how investors should interpret the long-term outlook based on current developments. What’s Behind the Recent Stock Volatility? So what’s going on with UnitedHealt

UnitedHealth Group ( $UnitedHealth(UNH)$ ) just took a brutal hit, plunging 18% after a shocking double blow: CEO Andrew Witty’s sudden resignation and the scrapping of its earnings outlook amid soaring medical costs. Meanwhile, President Trump’s new drug pricing executive order is rattling the biotech sector, piling pressure on an already shaky market. With UNH down 38% YTD and biotech facing a stormy Q2, investors are asking: Is this a screaming buy or a sinking ship? Let’s dive into the chaos and figure out what’s next. 🔎 What’s Going Down? UNH’s Meltdown: UnitedHealth dropped a bombshell, announcing Witty’s exit “for personal reasons” and yanking its full-year earnings guidance. The culprit? A relentless surge in medical costs that’s hammering